Chiron Pulminiq "Approvable" Pending Confirmatory Trial
This article was originally published in Pharmaceutical Approvals Monthly
An additional clinical trial is necessary to confirm the efficacy of Chiron’s Pulminiq inhaled immunosuppressant for prevention of lung transplant rejection, according to an FDA "approvable" letter received July 14.
You may also be interested in...
Chiron is requesting a priority review for its Pulminiq NDA, submitted October 14, which would place the user fee goal date for the aerosolized cyclosporine in April.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011